Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $6.2 million.

  • Precision Biosciences' Current Deferred Revenue rose 347028.57% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 347028.57%. This contributed to the annual value of $3.0 million for FY2024, which is 7543.0% down from last year.
  • According to the latest figures from Q3 2025, Precision Biosciences' Current Deferred Revenue is $6.2 million, which was up 347028.57% from $6.0 million recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Current Deferred Revenue ranged from a high of $53.1 million in Q1 2021 and a low of $175000.0 during Q3 2024
  • In the last 5 years, Precision Biosciences' Current Deferred Revenue had a median value of $19.7 million in 2022 and averaged $20.5 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 9899.68% in 2024, then skyrocketed by 347028.57% in 2025.
  • Quarter analysis of 5 years shows Precision Biosciences' Current Deferred Revenue stood at $21.2 million in 2021, then soared by 117.44% to $46.2 million in 2022, then plummeted by 73.95% to $12.0 million in 2023, then plummeted by 75.43% to $3.0 million in 2024, then soared by 111.3% to $6.2 million in 2025.
  • Its Current Deferred Revenue stands at $6.2 million for Q3 2025, versus $6.0 million for Q2 2025 and $5.7 million for Q1 2025.